MedTrace Logo

Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)

NCT00000559 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-07-12

No results posted yet for this study

Summary

To determine the effects, in postmenopausal women, of hormone replacement therapy on progression/regression of coronary heart disease, as measured by quantitative angiography.

Conditions

Interventions

DRUG

estrogen replacement therapy

DRUG

hormone replacement therapy

DRUG

estradiol

DRUG

medroxyprogesterone

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Howard Hodis · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-03-31
Completion
2001-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000559 on ClinicalTrials.gov